Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicitie

被引：44

作者：

Guha, Avirup ^{[1
]}

Armanious, Merna ^{[2
,3
]}

Fradley, Michael G. ^{[2
,3
]}

机构：

[1] Ohio State Univ, Div Cardiovasc Med, Columbus, OH 43210 USA

[2] Univ S Florida, Div Cardiovasc Med, Cardiooncol Program, 2 Tampa Gen Circle, Tampa, FL 33606 USA

[3] H Lee Moffitt Canc Ctr & Res Inst, Cardiooncol Program, 12902 USF Magnolia Dr, Tampa, FL 33612 USA

来源：

TRENDS IN CARDIOVASCULAR MEDICINE | 2019年 / 29卷 / 01期

关键词：

Cardio-oncology; Cardiotoxicity; Tyrosine kinase inhibitors; Proteasome inhibitors; CELL LUNG-CANCER; TYROSINE KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; METASTATIC BREAST-CANCER; HISTONE DEACETYLASE INHIBITORS; CHRONIC LYMPHOCYTIC-LEUKEMIA; PLATINUM-BASED CHEMOTHERAPY; ARTERIAL OCCLUSIVE DISEASE; DABRAFENIB PLUS TRAMETINIB; MISMATCH REPAIR-DEFICIENT;

D O I：

10.1016/j.tcm.2018.06.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There have been significant advances in the field of oncology leading to improved survival as a result of novel targeted and immunotherapies. Despite these improved outcomes, there is increased recognition of cardiotoxicities associated with these therapies that can lead to significant morbidity and mortality. As such, the field of cardio-oncology has seen significant growth over the last several years. In this review, we discuss recent advances in the field of cardio-oncology and provide a detailed discussion of the cardiovascular complications associated with novel cancer therapeutics including tyrosine kinase inhibitors, proteasome inhibitors, histone deacetylase inhibitors, CDK4/6 inhibitors and immunotherapies. (C) 2018 Elsevier Inc. All rights reserved.

引用

页码：29 / 39

页数：11

共 235 条

[1] Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML [J].

Aichberger, Karl J. ;

Herndlhofer, Susanne ;

Schernthaner, Gerit-Holger ;

Schillinger, Martin ;

Mitterbauer-Hohendanner, Gerlinde ;

Sillaber, Christian ;

Valent, Peter .

AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (07) :533-539

[2] The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state [J].

Alhawiti, Naif ;

Burbury, Kate L. ;

Kwa, Faith A. ;

O'Malley, Cindy J. ;

Shuttleworth, Peter ;

Alzard, Mohamad ;

Hamadi, Abdullah ;

Grigg, Andrew P. ;

Jackson, Denise E. .

THROMBOSIS RESEARCH, 2016, 145 :54-64

[3] Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial [J].

Alley, Evan W. ;

Lopez, Juanita ;

Santoro, Armando ;

Morosky, Anne ;

Saraf, Sanatan ;

Piperdi, Bilal ;

van Brummelen, Emilie .

LANCET ONCOLOGY, 2017, 18 (05) :623-630

[4] Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial [J].

Amadori, Sergio ;

Suciu, Stefan ;

Selleslag, Dominik ;

Aversa, Franco ;

Gaidano, Gianluca ;

Musso, Maurizio ;

Annino, Luciana ;

Venditti, Adriano ;

Voso, Maria Teresa ;

Mazzone, Carla ;

Magro, Domenico ;

De Fabritiis, Paolo ;

Muus, Petra ;

Alimena, Giuliana ;

Mancini, Marco ;

Hagemeijer, Anne ;

Paoloni, Francesca ;

Vignetti, Marco ;

Fazi, Paola ;

Meert, Liv ;

Ramadan, Safaa Mahmoud ;

Willemze, Roel ;

de Witte, Theo ;

Baron, Frederic .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (09) :972-+

[5]

[Anonymous], 2018, N Engl J Med, V379, P2582, DOI 10.1056/NEJMx180043

[6]

von Minckwitz Gunter, 2017, N Engl J Med, V377, P122, DOI [10.1056/NEJMx170011, 10.1056/NEJMoa1703643]

[7]

[Anonymous], JAMA ONCOL

[8]

[Anonymous], 2018, BLOOD

[9]

[Anonymous], 2015, Blood

[10]

[Anonymous], HEM ONC CANC APPR SA

← 1 2 3 4 5 6 7 8 9 10 →